UA98955C2 - Гетероциклические соединения и их применение - Google Patents

Гетероциклические соединения и их применение

Info

Publication number: UA98955C2
Authority: UA; Ukraine
Prior art keywords: inflammatory; disorders; myelo; restricted; diseases
Prior art date: 2007-03-23

Application number

UAA200910741A

Other languages

English (en)

Ukrainian (uk)

Inventor

И. Чень

Тимоти Д. Кашинг

Джейсон А. Дюке

Лопес де Турисо Феликс Гонзалез

Сяолинь Хао

Сяо Хе

Брайан Лукас

Лоренс Р. Макги

Андрэас Рейчелт

Роберт М. Рзаса

Дженифер Сеганиш

Йонсук Шин

Давэй Чжан

Original Assignee

Амген Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-23

Filing date

2008-03-24

Publication date

2012-07-10

2008-03-24 Application filed by Амген Инк. filed Critical Амген Инк.

2012-07-10 Publication of UA98955C2 publication Critical patent/UA98955C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

UAA200910741A 2007-03-23 2008-03-24 Гетероциклические соединения и их применение UA98955C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US91956807P	2007-03-23	2007-03-23

Publications (1)

Publication Number	Publication Date
UA98955C2 true UA98955C2 (ru)	2012-07-10

Family

ID=39645618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200910741A UA98955C2 (ru)	2007-03-23	2008-03-24	Гетероциклические соединения и их применение

Country Status (24)

Country	Link
US (6)	US8193199B2 (ru)
EP (2)	EP3045458A1 (ru)
JP (2)	JP5527761B2 (ru)
KR (1)	KR101504773B1 (ru)
CN (1)	CN101715453B (ru)
AU (1)	AU2008231304B2 (ru)
BR (1)	BRPI0809141A2 (ru)
CA (1)	CA2681136C (ru)
CR (2)	CR11053A (ru)
DK (1)	DK2137186T3 (ru)
EA (1)	EA017389B1 (ru)
ES (1)	ES2563458T3 (ru)
HR (1)	HRP20160350T1 (ru)
HU (1)	HUE028954T2 (ru)
IL (1)	IL200867A (ru)
MX (1)	MX2009009968A (ru)
NZ (1)	NZ579834A (ru)
PL (1)	PL2137186T3 (ru)
PT (1)	PT2137186E (ru)
RS (1)	RS54706B1 (ru)
SI (1)	SI2137186T1 (ru)
UA (1)	UA98955C2 (ru)
WO (1)	WO2008118468A1 (ru)
ZA (1)	ZA201308294B (ru)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008520744A (ja)	2004-11-19	2008-06-19	ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	抗炎症性ピラゾロピリミジン
CA2909277A1 (en)	2006-04-04	2007-10-11	Kevan M. Shokat	Kinase antagonists
PL2137186T3 (pl)	2007-03-23	2016-09-30		Związki heterocykliczne i ich zastosowania
US7705018B2 (en) *	2007-03-23	2010-04-27	Amgen Inc.	Substituted quinolines and their uses in treatment of inflammatory and related conditions
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
ES2587738T3 (es)	2007-12-21	2016-10-26	Ucb Biopharma Sprl	Derivados de quinoxalina y quinolina como inhibidores de quinasa
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2240451B1 (en)	2008-01-04	2017-08-09	Intellikine, LLC	Isoquinolinone derivatives substituted with a purine useful as PI3K inhibitors
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Kinase inhibitors and methods of use
AU2009260447B2 (en) *	2008-05-30	2012-03-29	Amgen Inc.	Inhibitors of PI3 kinase
WO2010006086A2 (en)	2008-07-08	2010-01-14	Intellikine, Inc.	Kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
DK2358720T3 (en)	2008-10-16	2016-06-06	Univ California	Heteroarylkinaseinhibitorer fused-ring
GB0819593D0 (en)	2008-10-24	2008-12-03	Ucb Pharma Sa	Therapeutic agents
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
GB0821693D0 (en) *	2008-11-27	2008-12-31	Ucb Pharma Sa	Therapeutic agents
JP2012517448A (ja) *	2009-02-11	2012-08-02	リアクションバイオロジーコープ．	選択的キナーゼ阻害剤
ES2598358T3 (es)	2009-02-13	2017-01-27	Ucb Pharma, S.A.	Derivados de quinolina como inhibidores de PI3K quinasa
WO2010100405A1 (en)	2009-03-06	2010-09-10	Ucb Pharma S.A.	Triazine derivatives as kinase inhibitors
JPWO2010125799A1 (ja)	2009-04-27	2012-10-25	塩野義製薬株式会社	Ｐｉ３ｋ阻害活性を有するウレア誘導体
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
GB0908957D0 (en) *	2009-05-22	2009-07-01	Ucb Pharma Sa	Therapeutic agents
SG176986A1 (en) *	2009-06-25	2012-02-28	Amgen Inc	Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CA2766100C (en)	2009-06-29	2018-05-22	Incyte Corporation	Pyrimidinones as pi3k inhibitors
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
WO2011058112A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrazole derivatives as kinase inhibitors
EP2499126B1 (en)	2009-11-12	2015-01-07	UCB Pharma, S.A.	Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
EP2499129B1 (en)	2009-11-12	2014-07-30	UCB Pharma, S.A.	Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058109A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
WO2011058111A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Aminopurine derivatives as kinase inhibitors
ES2442369T3 (es)	2009-11-12	2014-02-11	Ucb Pharma, S.A.	Derivados de quinolina y quinoxalina como inhibidores de cinasa
WO2011075630A1 (en) *	2009-12-18	2011-06-23	Incyte Corporation	Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
JP2013514989A (ja) *	2009-12-18	2013-05-02	アムジエン・インコーポレーテツド	複素環式化合物およびその使用法
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011093365A1 (ja) *	2010-01-27	2011-08-04	協和発酵キリン株式会社	含窒素複素環化合物
WO2011130342A1 (en)	2010-04-14	2011-10-20	Incyte Corporation	FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2011163195A1 (en)	2010-06-21	2011-12-29	Incyte Corporation	Fused pyrrole derivatives as pi3k inhibitors
EP2588473A1 (en) *	2010-06-30	2013-05-08	Amgen Inc.	Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
MX2012015135A (es) *	2010-07-01	2013-05-06	Amgen Inc	Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
JP2013530236A (ja) *	2010-07-01	2013-07-25	アムジエン・インコーポレーテツド	Ｐｉ３ｋ活性の阻害剤としての複素環式化合物およびその用途
AU2011272850A1 (en)	2010-07-02	2013-01-10	Amgen Inc.	Heterocyclic compounds and their use as inhibitors of PI3K activity
AR082799A1 (es) *	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
US9670212B2 (en)	2010-09-14	2017-06-06	Exelixis, Inc.	Inhibitors of PI3K-delta and methods of their use and manufacture
JP2013541591A (ja) *	2010-11-04	2013-11-14	アムジエン・インコーポレーテツド	複素環化合物およびそれらの使用
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
AU2011329806A1 (en) *	2010-11-17	2013-05-30	Amgen Inc.	Quinoline derivatives as PIK3 inhibitors
ES2764848T3 (es)	2010-12-20	2020-06-04	Incyte Holdings Corp	N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
AR084824A1 (es)	2011-01-10	2013-06-26	Intellikine Inc	Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
TWI592411B (zh)	2011-02-23	2017-07-21	英特爾立秦有限責任公司	激酶抑制劑之組合及其用途
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
WO2013012918A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
WO2013032591A1 (en)	2011-08-29	2013-03-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
WO2013077921A2 (en)	2011-09-02	2013-05-30	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
KR102131612B1 (ko)	2011-09-02	2020-07-08	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
EP2760845B1 (en)	2011-09-27	2016-11-16	Amgen Inc.	Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
EP2763994A4 (en) *	2011-10-04	2015-08-26	Gilead Calistoga Llc	NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
ES2661510T3 (es)	2011-12-15	2018-04-02	Novartis Ag	Uso de inhibidores de la actividad o función de PI3K
US20150011569A1 (en) *	2011-12-15	2015-01-08	Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine	NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru)	2012-09-26	2016-11-20	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния	Модулирование ire1
RU2702908C2 (ru)	2012-11-01	2019-10-14	Инфинити Фармасьютикалз, Инк.	Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2951168B1 (en) *	2013-01-31	2017-01-04	Vertex Pharmaceuticals Incorporated	Quinoline and quinoxaline amides as modulators of sodium channels
JP6417338B2 (ja)	2013-02-19	2018-11-07	アムジエン・インコーポレーテツド	癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物
AU2014236812B2 (en)	2013-03-14	2018-03-01	Amgen Inc.	Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JOP20200296A1 (ar)	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط
EA201690713A1 (ru)	2013-10-04	2016-08-31	Инфинити Фармасьютикалз, Инк.	Гетероциклические соединения и их применения
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EA036942B1 (ru)	2013-11-11	2021-01-18	Эмджен Инк.	Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
CA2931431A1 (en)	2013-12-05	2015-06-11	Acerta Pharma B.V.	Therapeutic combination of a pi3k inhibitor and a btk inhibitor
SG11201607705XA (en)	2014-03-19	2016-10-28	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
AR100289A1 (es)	2014-05-06	2016-09-21	Amgen Inc	Formas de un inhibidor de pi3k
CN104086551B (zh) *	2014-06-06	2016-09-21	人福医药集团股份公司	化合物及其制备方法和用途
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
KR20170082490A (ko)	2014-07-04	2017-07-14	루핀 리미티드	Pi3k 억제제로서 퀴놀리지논 유도체
EP2974729A1 (en) *	2014-07-17	2016-01-20	Abivax	Quinoline derivatives for use in the treatment of inflammatory diseases
TW201618773A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
US20170239351A1 (en)	2014-08-11	2017-08-24	Acerta Pharma B.V.	Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
PL3179991T3 (pl)	2014-08-11	2022-02-14	Acerta Pharma B.V.	Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016061280A1 (en) *	2014-10-14	2016-04-21	La Jolla Institute Of Allergy & Immunology	Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
TW202204345A (zh)	2015-01-16	2022-02-01	美商通用醫院公司	改善mRNA剪接之化合物
US9637488B2 (en)	2015-01-29	2017-05-02	Fuqiang Ruan	Heterocyclic compounds as inhibitors of class I PI3KS
SI3831833T1 (sl)	2015-02-27	2023-03-31	Incyte Holdings Corporation	Postopki za pripravo inhibitorja PI3K
CN106008479B (zh) *	2015-03-06	2020-01-10	南京圣和药业股份有限公司	作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
GB201506786D0 (en) *	2015-04-21	2015-06-03	Ucb Biopharma Sprl	Therapeutic use
WO2016183063A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN114230571B (zh)	2015-09-14	2025-07-08	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
CN108472298B (zh)	2015-11-24	2021-04-20	深圳阿拉丁医疗科技有限公司	选择性激酶抑制剂
CN108290898B (zh)	2016-03-05	2020-09-08	杭州征祥医药有限公司	作为磷脂酰肌醇3-激酶抑制剂的喹啉类似物
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN109640999A (zh)	2016-06-24	2019-04-16	无限药品股份有限公司	组合疗法
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
CN108069899B (zh) *	2016-11-18	2021-01-08	中国科学院大连化学物理研究所	一种制备2,3-取代喹啉类衍生物的方法
US11066420B2 (en)	2017-05-01	2021-07-20	Sanford Burnham Prebys Medical Discovery Institute	Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
ES2985118T3 (es)	2017-09-08	2024-11-04	Amgen Inc	Inhibidores de KRAS G12C y métodos de uso de los mismos
US10442799B1 (en)	2018-04-07	2019-10-15	Fuqiang Ruan	Heterocyclic compounds and uses thereof
EP3788038B1 (en)	2018-05-04	2023-10-11	Amgen Inc.	Kras g12c inhibitors and methods of using the same
IL278889B2 (en)	2018-06-01	2025-11-01	Incyte Corp	Dosing regimen for the treatment of pi3k related disorders
EP3807276B1 (en)	2018-06-12	2025-12-10	Amgen Inc.	Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7408635B2 (ja)	2018-08-31	2024-01-05	アムジエン・インコーポレーテツド	Ｍｄｍ２阻害剤を調製する方法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3669873A1 (en)	2018-12-20	2020-06-24	Abivax	Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
KR20250159270A (ko)	2019-05-21	2025-11-10	암젠 인크	고체 상태 형태
CN112574176B (zh) *	2019-09-27	2024-03-15	隆泰申医药科技(南京)有限公司	一种杂芳基类化合物及其应用
WO2021076655A1 (en)	2019-10-15	2021-04-22	Amgen Inc.	Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en)	2019-12-16	2023-01-26	Amgen Inc.	Dosing regimen of kras g12c inhibitor
CN114276326B (zh) *	2021-03-09	2022-11-11	南京征祥医药有限公司	喹啉化合物的盐及制备方法和应用
CN113218936B (zh) *	2021-06-07	2021-09-10	江苏欣诺科催化剂有限公司	锇酸钾的纯度检测方法
CN117916235A (zh) *	2021-08-11	2024-04-19	泰州亿腾景昂药业股份有限公司	周期蛋白依赖性激酶抑制剂
US12168662B1 (en)	2023-12-15	2024-12-17	King Faisal University	Pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridines compounds as CK2 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6043062A (en)	1995-02-17	2000-03-28	The Regents Of The University Of California	Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en)	1996-06-01	1996-08-07	Ludwig Inst Cancer Res	Novel lipid kinase
US5858753A (en)	1996-11-25	1999-01-12	Icos Corporation	Lipid kinase
US5822910A (en)	1997-10-02	1998-10-20	Shewmake; I. W.	Fishing line tensioning device
US20030004174A9 (en) *	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
US20050153989A1 (en) *	2004-01-13	2005-07-14	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1750727A2 (en) *	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
JP5033119B2 (ja) *	2005-04-25	2012-09-26	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	キナーゼ阻害剤としての新規アザ複素環化合物
WO2007103756A2 (en)	2006-03-02	2007-09-13	Smithkline Beecham Corporation	Thiazolones for use as pi3 kinase inhibitors
EP1996191A4 (en)	2006-03-02	2010-05-19	Glaxosmithkline Llc	THIAZOLONE AS A PI3 KINASE INHIBITOR
WO2008097976A1 (en)	2007-02-09	2008-08-14	Kalypsys, Inc.	Heterocyclic modulators of tgr5 for treatment of disease
PL2137186T3 (pl) *	2007-03-23	2016-09-30		Związki heterocykliczne i ich zastosowania
US8367702B2 (en)	2007-09-26	2013-02-05	Astellas Pharma Inc.	Quinolone derivative
ES2587738T3 (es) *	2007-12-21	2016-10-26	Ucb Biopharma Sprl	Derivados de quinoxalina y quinolina como inhibidores de quinasa
CA2738429C (en) *	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
GB0819593D0 (en) *	2008-10-24	2008-12-03	Ucb Pharma Sa	Therapeutic agents
GB0821693D0 (en) *	2008-11-27	2008-12-31	Ucb Pharma Sa	Therapeutic agents
ES2598358T3 (es)	2009-02-13	2017-01-27	Ucb Pharma, S.A.	Derivados de quinolina como inhibidores de PI3K quinasa
JP5789252B2 (ja) *	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
SG176986A1 (en) *	2009-06-25	2012-02-28	Amgen Inc	Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
EP2499126B1 (en)	2009-11-12	2015-01-07	UCB Pharma, S.A.	Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
JP2013514989A (ja)	2009-12-18	2013-05-02	アムジエン・インコーポレーテツド	複素環式化合物およびその使用法

2008
- 2008-03-24 PL PL08727163.1T patent/PL2137186T3/pl unknown
- 2008-03-24 HU HUE08727163A patent/HUE028954T2/en unknown
- 2008-03-24 CA CA2681136A patent/CA2681136C/en active Active
- 2008-03-24 BR BRPI0809141-2A patent/BRPI0809141A2/pt not_active Application Discontinuation
- 2008-03-24 EP EP16152820.3A patent/EP3045458A1/en not_active Withdrawn
- 2008-03-24 AU AU2008231304A patent/AU2008231304B2/en active Active
- 2008-03-24 KR KR1020097022066A patent/KR101504773B1/ko active Active
- 2008-03-24 NZ NZ579834A patent/NZ579834A/en unknown
- 2008-03-24 JP JP2009554600A patent/JP5527761B2/ja active Active
- 2008-03-24 EP EP08727163.1A patent/EP2137186B1/en active Active
- 2008-03-24 RS RS20160208A patent/RS54706B1/sr unknown
- 2008-03-24 HR HRP20160350TT patent/HRP20160350T1/hr unknown
- 2008-03-24 WO PCT/US2008/003962 patent/WO2008118468A1/en not_active Ceased
- 2008-03-24 US US12/079,406 patent/US8193199B2/en active Active
- 2008-03-24 MX MX2009009968A patent/MX2009009968A/es active IP Right Grant
- 2008-03-24 EA EA200901276A patent/EA017389B1/ru not_active IP Right Cessation
- 2008-03-24 DK DK08727163.1T patent/DK2137186T3/en active
- 2008-03-24 ES ES08727163.1T patent/ES2563458T3/es active Active
- 2008-03-24 CN CN2008800170109A patent/CN101715453B/zh active Active
- 2008-03-24 UA UAA200910741A patent/UA98955C2/ru unknown
- 2008-03-24 PT PT87271631T patent/PT2137186E/pt unknown
- 2008-03-24 SI SI200831591T patent/SI2137186T1/sl unknown
2009
- 2009-09-10 IL IL200867A patent/IL200867A/en active IP Right Grant
- 2009-10-05 CR CR11053A patent/CR11053A/es unknown
2010
- 2010-07-21 CR CR11582A patent/CR11582A/es unknown
2012
- 2012-05-10 US US13/468,234 patent/US8901135B2/en active Active
- 2012-05-10 US US13/468,212 patent/US8586739B2/en active Active
2013
- 2013-10-22 JP JP2013218925A patent/JP5819382B2/ja active Active
- 2013-11-05 ZA ZA2013/08294A patent/ZA201308294B/en unknown
2014
- 2014-10-22 US US14/520,899 patent/US9873701B2/en active Active
2017
- 2017-12-13 US US15/841,153 patent/US20180105532A1/en not_active Abandoned
2019
- 2019-10-17 US US16/656,328 patent/US20200048265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20180105532A1 (en)	2018-04-19
US20120220585A1 (en)	2012-08-30
KR101504773B1 (ko)	2015-03-20
ES2563458T3 (es)	2016-03-15
HUE028954T2 (en)	2017-01-30
IL200867A (en)	2014-11-30
IL200867A0 (en)	2010-05-17
DK2137186T3 (en)	2016-04-18
ZA201308294B (en)	2014-07-30
JP5527761B2 (ja)	2014-06-25
US8193199B2 (en)	2012-06-05
SI2137186T1 (sl)	2016-04-29
JP2010522179A (ja)	2010-07-01
NZ579834A (en)	2012-03-30
RS54706B1 (sr)	2016-08-31
US9873701B2 (en)	2018-01-23
MX2009009968A (es)	2009-10-08
CN101715453A (zh)	2010-05-26
BRPI0809141A2 (pt)	2014-08-26
CR11053A (es)	2009-10-23
AU2008231304A1 (en)	2008-10-02
PT2137186E (pt)	2016-03-30
US8901135B2 (en)	2014-12-02
AU2008231304B2 (en)	2011-05-12
CN101715453B (zh)	2012-06-27
EP2137186A1 (en)	2009-12-30
EA200901276A1 (ru)	2010-04-30
JP5819382B2 (ja)	2015-11-24
WO2008118468A1 (en)	2008-10-02
EP3045458A1 (en)	2016-07-20
HRP20160350T1 (hr)	2016-05-06
EA017389B1 (ru)	2012-12-28
US8586739B2 (en)	2013-11-19
US20120220586A1 (en)	2012-08-30
US20150045361A1 (en)	2015-02-12
CA2681136C (en)	2012-05-22
PL2137186T3 (pl)	2016-09-30
US20090137581A1 (en)	2009-05-28
US20200048265A1 (en)	2020-02-13
CR11582A (es)	2011-01-10
CA2681136A1 (en)	2008-10-02
EP2137186B1 (en)	2016-01-27
KR20100015795A (ko)	2010-02-12
JP2014058526A (ja)	2014-04-03

Publication	Publication Date	Title
UA98955C2 (ru)	2012-07-10	Гетероциклические соединения и их применение
MX2011013666A (es)	2012-03-06	Compuestos heterociclicos y sus usos.
TN2012000449A1 (en)	2014-01-30	Heterocyclic compounds and their uses
MX2013007261A (es)	2013-11-04	Compuestos heterociclicos y sus usos.
MX2009009913A (es)	2009-10-16	Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
MX2011013667A (es)	2012-03-06	Compuestos heterociclicos y sus usos.
MX2012015135A (es)	2013-05-06	Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2011013510A (es)	2012-03-07	Compuestos heterociclicos y sus usos.
MX2012015134A (es)	2013-05-06	Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
MX2012015143A (es)	2013-07-03	Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
MX2011013901A (es)	2012-05-08	Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
MX2009010050A (es)	2009-10-12	Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
MX2012015147A (es)	2013-05-01	Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
PH12014502246A1 (en)	2014-12-15	Heterocyclic compounds and their uses
MX2022007140A (es)	2022-07-19	Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3).
PH12020551390A1 (en)	2021-11-22	AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
CL2012000795A1 (es)	2012-09-07	Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak); composicion farmaceutica que comprnde a uno de dichos compuestos; y su uso para la preparacion de medicamentos utiles en el tratamiento de alzheimer, cancer, artritis, leucemia, diabetes, enfermedades inflamatorias y autoinmunes, entre otras.
MX2017010348A (es)	2018-06-07	Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
MX2018011046A (es)	2019-05-06	Composiciones y metodos para tratar canceres.
CY1117196T1 (el)	2017-04-05	Ετεροκυκλικες ενωσεις και χρησεις αυτων
AR090705A1 (es)	2014-12-03	Compuestos de piridina y pirimidina y sus usos como inhibidores de fosfatidilinositol 3-quinasa (pi3k)
UY34748A (es)	2014-10-31	Compuestos heterocíclicos y sus usos